Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula
NCT ID: NCT02425423
Last Updated: 2015-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
100 participants
INTERVENTIONAL
2013-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of MIST on Esophageal Sensitivity in Patients With rGERD
NCT05429034
Effect of MIST on Esophageal Sensitivity in HV
NCT05427188
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
NCT00498082
Treatment Of Gastroesophageal Reflux Disease By Endoscopic Fundoplication, A Placebo-Controlled Study
NCT00235677
Acceptability and Tolerance Study of a Thickener
NCT05026476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
New thickened infant formula
New thickened formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
New thickened formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged ≤ 5 months old
* fully formula fed
* with at least 5 episodes of regurgitation per day
Exclusion Criteria
* Infants presenting symptoms of a complicated gastroesophageal reflux
* Infants presenting intestinal disorders
5 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yvan Vandenplas, MD
Role: PRINCIPAL_INVESTIGATOR
Universitair Ziekenhuis Brussel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatricians
Belgium, , Belgium
Universitair Ziekenhuis
Brussels, , Belgium
Pediatricians
France, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-01-SONAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.